Skip to main content

Table 1 Comparison of baseline demographic and clinical characteristics, indications, duration, and treatment strategy in patients who received tigecycline before and after the antibiotic stewardship program intervention

From: The effect of an antibiotic stewardship program on tigecycline use in a Tertiary Care Hospital, an intervention study

Characteristics

Patients treated with TGC before ASP (P1) (%)

(N = 153)

Patients treated with TGC after ASP (P2) (%)

(N = 116)

P

Age (years) (median; IQR)

68 (47–80)

70 (53–77)

0.314

 ≤ 65

72 (47.1%)

50 (43.1%)

0.519

 > 65

81 (52.9%)

66 (56.9%)

Gender

 Male

79 (51.6%)

64 (55.2%)

0.565

 Female

74 (48.4%)

52 (44.8%)

Comorbidities

 Cardiovascular disease

90 (58.8%)

83 (71.6%)

0.031

 Diabetes

46 (30.1%)

48 (41.4%)

0.054

 Respiratory disease

21 (13.7%)

19 (16.4%)

0.097

 Acute renal failure

35 (22.9%)

10 (8.6%)

0.002

 chronic kidney disease

19 (12.4%)

23 (19.8%)

0.097

 Chronic hepatic disease

6 (3.9%)

2 (1.7%)

0.472

 Neutropenia (ANC < 500 cells/µL)

30 (19.6%)

0

< 0.0001

 Malignancy

50 (32.7%)

22 (19.0%)

0.012

  Leukemia

24 (15.7%)

2 (1.7%)

< 0.0001

  Lymphoma

11 (7.2%)

1 (0.9%)

0.013

  Solid tumor

15 (9.8%)

19 (16.4%)

0.108

 Bone marrow transplantation

14 (9.2%)

2 (1.7%)

0.011

  Autologous

4 (2.6%)

1 (0.9%)

0.394

  Allogeneic

10 (6.5%)

1 (0.9%)

0.026

Use of vasopressors before TGC use by 24 h

37 (24.2%)

15 (12.9%)

0.021

Mechanical ventilation

35 (22.9%)

13 (11.2%)

0.013

Indications for TGC therapy

 FDA approved

29 (19%)

91 (78.4%)

< 0.0001

 Off-label

124 (81%)

25 (21.6%)

 

FDA-approved indications

 cSSTI

18 (11.8%)

56 (48.3%)

< 0.0001

 cIAI

4 (2.6%)

33 (28.3%)

< 0.0001

 CAP

7 (4.6%)

2 (1.7%)

0.082

Off-label indications

 HAP

30 (19.6%)

6 (5.2%)

0.001

 VAP

40 (26.1%)

4 (3.4%)

< 0.0001

 BSI

14 (9.2%)

0

0.001

 Sepsis

14 (9.2%)

3 (2.6%)

0.028

 UTI

6 (3.9%)

2 (1.7%)

0.472

 FN

24 (15.7%)

1 (0.9%)

< 0.0001

 Diabetic ulcer

8 (5.2%)

8 (6.9%)

0.567

Duration of TGC therapy regardless the indication (days) (median/IQR)

8 (5–13)

7 (5–9)

0.973

 ≤ 7 days

67 (43.8%)

64 (55.2%)

0.064

 > 10 days

55 (35.9%)

21 (18.1%)

0.001

 > 15 days

27 (17.6%)

7 (6%)

0.005

Duration of TGC therapy in cIAI (days) (median/IQR)

10 (7–12)

7 (4–8)

0.137

 > 5 daysa

3/4 (75%)

22/33 (66.7%)

0.9

Duration of TGC therapy in cSSTI (days) (median/IQR)

8 (5–11)

7 (5–10)

0.499

 > 7 daysb

10/18 (55.6%)

26/56 (46.4%)

0.5

 > 10 daysb

5/18 (27.8%)

12/56 (21.4%)

0.75

Treatment strategy of TGC

 Empiric

67 (43.8%)

63 (54.3%)

0.087

 Targeted

86 (56.2%)

53 (45.7%)

 Monotherapy

26 (17%)

47 (40.5%)

< 0.0001

 Combination therapyc

127 (83%)

69 (59.5%)

  1. ANC absolute neutrophil count, ASP antibiotic stewardship program, BSI blood-stream infection, CAP community-acquired pneumonia, cIAI complicated intra-abdominal infections, cSSTI complicated skin and soft tissue infection, d days, FN febrile neutropenia, HAP hospital-acquired pneumonia, IQR interquartile range, NA not applicable, P period, TGC tigecycline, UTI urinary tract infection, VAP ventilator-associated pneumonia
  2. aThe denominator is the total number of cIAI cases per each category
  3. bThe denominator is the total number of cSSTI cases per each category
  4. cCombination therapy for infections caused by Gram-negative bacteria